CEO Interview - MedStar LMU Dec 2020 - Acrobat pdf 135k 17 December 2020 Interview with Pro Medicus CEO, Dr Sam Hupert, where he discussed: A$18M 5-year MedStar Health contract LMU Klinikum A$10M 5-year deal announced in October 2020 New single vendor, offering Visage In The Cloud
17 December 2020; Company Announcement - PME Signs MedStar Health 17 Dec 2020 - Acrobat pdf 107k Highlights PME signs 5-year, A$18M deal with MedStar Health Visage to replace MedStar’s legacy PACS across their 10 hospitals, representing the largest health system in the Maryland/District of Columbia (DC) region Contract is for the full suite of Visage 7 modules – Visage 7 Viewer, Visage 7 Open Archive and Visage 7 Workflow Visage 7 platform to be fully deployed in the public-cloud Extends PME’s rapidly growing footprint in North America Transaction-based model with potential upside Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly-owned U.S. subsidiary, Visage Imaging, Inc., has signed a 5-year contract with MedStar Health (“MedStar”), the largest health system in the Maryland and Washington, D.C. metropolitan region. The contract, based on a transactional licensing model, will see the company’s complete enterprise imaging solution comprising Visage 7 Viewer, Visage 7 Open Archive and Visage 7 Workflow implemented across all of MedStar’s radiology and subspecialty imaging departments including MedStar Georgetown University Hospital. The implementation is notable in that it will provide MedStar with a fully cloud deployed environment on GCP (Google Cloud Platform), leveraging Visage’s native, cloud-engineered enterprise imaging technology. Planning for the rollout is to commence in Q2 FY21 with the first sites scheduled to go-live in Q3 FY21. “MedStar went through an extensive evaluation process including a pilot that not only benchmarked Visage 7 compared to on-premise systems from other vendors, it served to verify the speed of Visage 7 in the public-cloud,” said Dr Sam Hupert, Pro Medicus CEO. “Unlike systems from other vendors, Visage has been developed from the ground up for cloud deployment. Traditionally, our clients have deployed Visage in their own “private-cloud”
19 November 2020; Company Announcement - ZP Renewal Nov 2020 - Acrobat pdf 154k Highlights PME signs 5-year renewal contract with Zwanger-Pesiri Zwanger-Pesiri one of the largest private outpatient radiology providers in the U.S. Transaction-based model with potential upside Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly-owned U.S. subsidiary, Visage Imaging, Inc., has signed a 5-year renewal contract with Long Island based Zwanger-Pesiri, one of the largest private outpatient radiology providers in the U.S.. The contract, based on a transaction-based licensing model, will see the company’s Visage 7 technology continued to be used across all Zwanger-Pesiri locations for the next 5 years. “We have had a great partnership with Visage over the preceding 5 years,” said Dr Steve Mendelsohn, CEO of Zwanger-Pesiri. “The speed and capabilities of their software is unrivalled in the market. Since implementing it 5 years ago, we have experienced significant increases in radiologist productivity and clinical accuracy which has underpinned our substantial growth over that time.” “We are very pleased to have played such a key role in Zwanger-Pesiri’s growth over the past 5 years,” said Dr Sam Hupert, Pro Medicus CEO. “We believe our solution provides the best return on investment of any system in the market from both financial and clinical perspectives. We think the results we achieved at Zwanger-Persiri is validation of that.” Authorised by the Board of Pro Medicus Limited.
15 October 2020; Company Announcement - LMU Klinikum Munich - Acrobat pdf 118k Highlights PME signs 7-year, A$10M deal with LMU Klinikum LMU Klinikum is one of the largest university hospitals in Germany Visage technology to be deployed throughout LMU Klinikum’s imaging departments replacing systems from legacy vendors Extends PME’s footprint in the European hospital segment Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly- owned German subsidiary, Visage Imaging GmbH, has signed a 7-year A$10million contract with Munich based Ludwig-Maximilians-Universität (LMU Klinikum) one of the largest university hospitals in Europe. The contract will see the company’s Visage 7 technology implemented across all LMU Klinikum’s radiology and subspecialty imaging departments replacing existing legacy PACS systems with a single centralized instance of the Visage 7 Enterprise Imaging Platform. Visage is also used in the hospital’s state of the art operating theatre suite for HD video documentation and point-of-care Ultrasound archival and viewing. LMU Faculty of Medicine is the largest medical training institution in southern Germany and regarded as one of the top academic hospitals in Europe. The implementation is scheduled to commence in December 2020. “We look forward to taking our partnership with Visage to the next level as we implement their technology across our radiology department,” said Dr Kurt Kruber, CIO of LMU Klinikum. “The Visage platform provides a highly scalable and reliable platform combined with sophisticated clinical features that will support us in both day-to-day patient care and advanced research.” “We are very excited about this project,” said Dr Malte Westerhoff, Managing Director of Visage Imaging GmbH. “LMU Klinikum is a thought leader in making a digital strategy a core principle of their operations. We are confident that our technology and
CEO Interview NYU Sept 2020 - Acrobat pdf 195k 11 September 2020 Interview with Pro Medicus CEO, Dr Sam Hupert, where he discussed: $25m NYU Langone contract Multi-year Research Collaboration Agreement PME to establish R&D hub in New York City Update on pipeline
11 September 2020; Company Announcement NYU Research Collaboration Sept 2020 - Acrobat pdf 114k Highlights PME signs multi-year Research Collaboration agreement with NYU Langone Health PME and NYU Langone Health to jointly develop next-generation enterprise imaging solutions PME to establish Research/R&D Hub in New York City New Hub to form the foundation for Visage research activities in the U.S. Significant investment in future PME products Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly- owned U.S. subsidiary, Visage Imaging, Inc., has signed a multi-year Research Collaboration agreement with NYU Langone Health (NYU Langone), one of the most highly regarded health systems in North America. Under the terms of the agreement, the two parties will work together to design and develop next-generation products for enterprise imaging in areas such as workflow optimization, integration with multi-vendor reporting platforms, as well as integration of artificial intelligence (AI) technology. NYU Langone will also become a member of the Visage AI Accelerator program. “This is a major milestone for our company,” said Dr Sam Hupert, Pro Medicus CEO. “We changed the paradigm of what a diagnostic imaging (PACS) product should be by natively integrating 3D and advanced visualisation into a single platform. We believe this, combined with our proprietary streaming platform, has given us an 18 to 24 month technology lead. We are now looking at what is next, what a system would look like in say 3 to 5 years, and are starting to do the research and development to make that a reality and then be the first to commercialise it.” In addition to working on-premise at NYU Langone, PME will establish its own R&D Hub in New York City to spearhead PME’s research and
11 September 2020; Company Announcement NYU Sept 2020 - Acrobat pdf 118k Highlights PME signs 7-year, A$25M deal with NYU Langone Health NYU Langone ranked in the 10 best hospitals by U.S. News & World Report 2020- 2021 Tier 1 academic institution which includes the renowned NYU Grossman School of Medicine Visage technology to be deployed throughout NYU’s imaging departments replacing systems from legacy vendors Extends PME’s footprint in the tier 1 U.S. academic hospital segment Transaction-based model with potential upside Leading health imaging company Pro Medicus Limited [ASX: PME] today announced its wholly-owned U.S. subsidiary, Visage Imaging, Inc., has signed a 7-year contract with NYU Langone Health (NYU Langone), one of the largest health systems in the state of New York and one of the most respected and innovative healthcare institutions in North America. The contract, based on a transaction-based licensing model, will see the company’s Visage 7 technology implemented across all of NYU Langone’s radiology and subspecialty imaging departments, including breast imaging, replacing all existing legacy PACS with a single centralized instance of the Visage 7 Enterprise Imaging Platform. The implementation will span 6 hospitals and numerous additional locations across the NYU Langone healthcare network. Planning for the rollout is to commence in Q2 FY21, with the first sites scheduled to go-live in Q3 FY21. “NYU Langone completed a thorough selection process that required the final round of vendors to perform extensive on-site pilots. This enabled NYU to assess the differences between systems and, importantly, do so in their production environment, which is the ultimate test of how a product will perform,” said Dr Sam Hupert, Pro Medicus CEO. “Winning this deal further validates our belief that we have a unique and highly differentiated
24 August 2020 Pro Medicus Limited (ASX:PME) hosted a webcast conference call on Thursday, 20 August 2020 at 11.00am (AEST), where Dr Sam Hupert, Pro Medicus CEO, discussed PME’s Full-Year FY 2020 Results. This is the archived webcast of the discussion.
CEO Interview FY2020 - Acrobat pdf 194k 20 August 2020 Interview with Pro Medicus CEO, Dr Sam Hupert, where he discussed: Financial results for the year ended 30 June 2020 COVID-19 effects on the business Strong cash flows and dividend payout Doing business in the COVID-19 environment Current pipeline and prospects
20 August 2020; Company Announcement - Pro Medicus Limited Full Year Results - Acrobat pdf 118k Highlights Strong growth continues despite restrictions of COVID-19 Revenue from underlying operations $56.8m – up 23.9% Underlying profit before tax $30.2m – up 33.4% Net profit after tax $23.1m – up 20.7% Margins increase to 52.5% Cash reserves $43.4m – up 34.3% Strong balance sheet - No debt Fully franked final dividend 6c per share. Total FY20 dividend up 14.3%. Three key contracts announced during the period Leading health imaging company Pro Medicus Limited [ASX: PME] today announced a full- year net profit of $23.1m for the 12 months to the end of June 2020, 20.7% higher than for the previous corresponding period. Underlying profit before tax, which excludes a $3.0m one-off capital sale to the German government in the previous period, was $30.24m, an increase of 33.4%. Revenue from underlying operations, increased by 23.9% to $56.8m. There was solid growth in key jurisdictions – North America (up 23.7%) and Australia (up 19.2%) – while revenue from European operations fell 37.7%, largely as a result of the one-off sale to the German government in the previous period. The company's cash reserves at 30 June 2020 were $43.4m, a rise of 34.3%. Pro Medicus announced a final fully franked dividend of 6c per share, taking total dividends for the year to 12c per share. The company remains debt-free. During the year Pro Medicus announced three key contract wins: Ohio State University, November 2019 – a $9m five-year contract with the Ohio State University Wexner Medical Center, a large multi-disciplinary academic medical centre in Columbus, Ohio. Nines Inc, December 2019 – a $6m five-year deal with Palo Alto-based Nines that will see